Table 1

 Baseline demographic and clinical characteristics of the patients

CharacteristicTreatment group
HAART (n = 18)HAART + bosentan (n = 18)
Data are mean number (%) or median (range).
CDC, Centers for Disease Control and Prevention; HAART, highly active antiretroviral therapy; HBV, hepatitis B virus; HBC, hepatitis C virus; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance.
Men15 (83%)16 (88%)
Age (years)45 (37–55)47 (36–58)
Homosexuals13 (72%)11 (61%)
Heterosexuals4 (22%)5 (28%)
Unknown factors1 (6%)2 (11%)
Duration of documented seropositivity (months)25 (11–32)28 (14–43)
CD4 count (cells/mm3)330 (175–653)350 (160–730)
Plasma HIV RNA (log10)copies/ml4.3 (3.3–5.5)4.5 (3.5–6.1)
Positivity for HBV/HCV3 (17%)2 (11%)
CDC class
    A13 (17%)2 (11%)
    A212 (66%)13 (72%)
    A33 (17%)3 (17%)
Antiretroviral drug given at enrolment
    Combination (ritonavir + indinavir)6 (33%)7 (39%)
    Nelfinavir3 (17%)2 (11%)
    Zidovudine18 (100%)18 (100%)
    Didanosine18 (100%)18 (100%)
    Nevirapine3 (17%)2 (11%)
    Efavirenz6 (33%)7 (39%)
Cardiopulmonary haemodynamic parameters
    Right atrial pressure (mm Hg)11 (6–18)12 (7–17)
    mPAP (mm Hg)52 (42–63)53 (44–65)
    PCWP (mm Hg)7.5 (5–8)7.7 (6–9)
    PVR (dyn·s·cm−5)770 (610–930)780 (625–950)
    Cardiac index (l/min/m2)2.7 (2.2–3.3)2.6 (2–3.2)
NYHA class
    III17 (94%)16 (89%)
    IV1 (6%)2 (11%)
Six-minute walk distance (m)270 (197–343)265 (205–325)
Duration of symptoms (months)12 (6–18)11 (5–16)
Concomitant PAH treatment
    Anticoagulants1 (6%)2 (11%)
    Oxygen1 (6%)2 (11%)